KORU Medical Systems Inc. (KRMD) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, KORU Medical Systems Inc. (NASDAQ: KRMD) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $3.05 (+2.01% 1D, market cap $138.1M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, KRMD ranks #443 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), KRMD carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of 62.3%, and ROIC of -28.7%. By comparison, LUNG (Pulmonx Corporation) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $129.1M) and SKYA (SkyAI Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $128.4M). Among the 5-stock peer group, KRMD leads on earnings multiple (N/A) while KRMD leads on capital efficiency (-28.7% ROIC).
Per KRMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000704440), KORU Medical Systems Inc. generated $41.1M in revenue (+22.2% YoY), -$2.6M in net income, and $462.4K in free cash flow against $28.2M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 8.05 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL FY 2025 (10-K): 1.1% FCF Margin ($462.4K FCF) & 62.3% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While KRMD currently carries a cautious 41/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Clean SEC annual filing review with no major hidden accounting time-bombs.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.13) and Max Pain ($3.20) forces dealer call-delta covering toward $6.94.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
KORU Medical Systems Inc. (KRMD) surged +2.01% to $3.05, trading at 5% of its 52-week range ($2.86 – $6.61). Stretched risk/reward at current multiples (-29% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering KORU Medical Systems Inc. (KRMD) market action, institutional positioning, and fundamental catalysts.
TradingView report covering KORU Medical Systems Inc. (KRMD) market action, institutional positioning, and fundamental catalysts.
Investing.com UK report covering KORU Medical Systems Inc. (KRMD) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering KORU Medical Systems Inc. (KRMD) market action, institutional positioning, and fundamental catalysts.
Investing.com Canada report covering KORU Medical Systems Inc. (KRMD) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering KORU Medical Systems Inc. (KRMD) market action, institutional positioning, and fundamental catalysts.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +22.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on KRMD today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for KRMD. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, KORU Medical Systems Inc. (KRMD) ranks #443 by composite RQD confidence (41/100, grade D-) and #613 by equity capitalization ($138.1M). Within this direct 5-issuer industry benchmark cohort, KRMD leads on earnings valuation at N/A trailing P/E, while KRMD leads on capital efficiency and profitability with -28.7% ROIC and 62.3% gross margin. SKYA currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with KRMD at 41/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| KRMD
ACTIVE
KORU Medical Systems Inc. | D- | 41/100 | — | 62.3% | -28.7% | +2.01% | $138.1M | Benchmark Subject |
| LUNG Pulmonx Corporation | D- | 38/100 | — | 74.2% | -35.0% | -14.14% | $129.1M | /lung-vs-krmd → |
| SKYA SkyAI Inc. | D- | 43/100 | — | -30.0% | -35.0% | -1.35% | $128.4M | /skya-vs-krmd → |
| STIM Neuronetics Inc. | E | 28/100 | — | 48.5% | -35.0% | -8.44% | $171.4M | /stim-vs-krmd → |
| APYX Apyx Medical Corporation | E | 21/100 | — | 62.5% | -28.9% | 0.00% | $109.5M | /apyx-vs-krmd → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), KORU Medical Systems Inc. (KRMD) reported GAAP revenue of $41.1M (+22.2% vs. FY2024 revenue of $33.6M , and +44.2% cumulative change since FY2023) , GAAP net income of -$2.6M, operating cash flow of $462.4K, and free cash flow of $462.4K (+244.6% YoY). On the balance sheet, KRMD closed FY2025 with $28.2M in total assets against $0 in total debt (Altman Z-Score: 8.05, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $41.1M | -$2.6M | $462.4K | $462.4K | $28.2M | — |
| FY2024 (FY) | 2024-12-31 | $33.6M | -$6.1M | -$319.7K | -$319.7K | $27.2M | — |
| FY2023 (FY) | 2023-12-31 | $28.5M | -$13.7M | -$4.9M | -$4.9M | — | — |
As of 2026-11-03, KORU Medical Systems Inc. (NASDAQ: KRMD) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $3.05 (+2.01% 1D, market cap $138.1M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, KRMD ranks #443 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), KRMD carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of 62.3%, and ROIC of -28.7%. By comparison, LUNG (Pulmonx Corporation) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $129.1M) and SKYA (SkyAI Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $128.4M). Among the 5-stock peer group, KRMD leads on earnings multiple (N/A) while KRMD leads on capital efficiency (-28.7% ROIC).
Per KRMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000704440), KORU Medical Systems Inc. generated $41.1M in revenue (+22.2% YoY), -$2.6M in net income, and $462.4K in free cash flow against $28.2M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
KRMD last traded at $3.05 (+2.01% on volume of 221,701 shares), positioning the stock -2.56% below its 50-day simple moving average ($3.13) and -23.56% below its 200-day simple moving average ($3.99). Across its 52-week range of $2.86 to $6.61, KRMD sits at the 5.1% percentile with a 14-day RSI of 44.5 (NEUTRAL RANGE) and an implied next-earnings move of ±9.7% ($2.75 to $3.35).
KORU Medical Systems Inc. (KRMD) earns a live Roarable RQD composite score of 41/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $3.05 (+2.01% 1D, market capitalization $138.1M).
KORU Medical Systems Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry (per the SEC profile). The profile does not describe its products, customers, or revenue model in source data. Market capitalization is $0.1B. Revenue of $41.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), KORU Medical Systems Inc. (KRMD) reported $41.1M in annual revenue (up from $33.6M in FY2024, +22.2% YoY) and -$2.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($28.5M revenue, -$13.7M net income) through FY2025, KRMD scaled operating cash flow to $462.4K and free cash flow to $462.4K, backed by $28.2M in total assets against $0 in total debt.
The sector and industry classification (Health Care; Medical/Dental Instruments) is the only contextual link provided. A prospective investor should note that the absence of mapped dependencies means second-order bottlenecks cannot be identified from the source data.
Real-time company headlines, analyst actions, and sector developments for KORU Medical Systems Inc. (KRMD) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering KORU Medical Systems Inc. (KRMD) market action, institutional positioning, and fundamental catalysts.
TradingView report covering KORU Medical Systems Inc. (KRMD) market action, institutional positioning, and fundamental catalysts.
Investing.com UK report covering KORU Medical Systems Inc. (KRMD) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering KORU Medical Systems Inc. (KRMD) market action, institutional positioning, and fundamental catalysts.
Investing.com Canada report covering KORU Medical Systems Inc. (KRMD) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering KORU Medical Systems Inc. (KRMD) market action, institutional positioning, and fundamental catalysts.
Picked up a starter position in KRMD in my $100K Virtual Cash book at $2.99. The balance sheet scores strongest in the rating (Altman Z 8.05, Piotroski F 7/9, Debt/Equity 0.5) and revenue grew from $28.5M to $41.1M while the net loss narrowed from -$13.7M to -$2.6M.. Trading inside a $2.86–$6.61 52-week range with 0.31% FCF yield gives solid downside support if Medical/Dental Instruments multiples expand this quarter.
@MultipleCompression Shorting a 4/20 institutional whale-flow stock at $2.99 is dangerous when funds are rotating into Health Care.
Here is the bear case nobody on the bull side wants to address on KRMD: ROIC of -28.7%, an FCF yield of 0.31%, and a beta of 1.0 with a macro regime fit score of 5/20 leave the stock without cash-generation or defensive support, and the rating carries a distribution warning.. At current EV/EBITDA multiples, even a small guidance miss in Medical/Dental Instruments triggers a 12-15% air pocket.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: